Impurities in Food and Pharmaceuticals - can Risk Assessment and Regulation be Aligned?

Introduction

The health risk assessment of impurities is a key part of assuring the safety of food and drugs. Despite the scientific theory of hazard and risk assessment being shared by the two sectors, there are several significant regulatory differences. This event will look in detail at two case studies – titanium dioxide, which is under scrutiny in the food sector but is widely used in pharmaceuticals, and nitrosamines, which are naturally formed in certain foods but are extremely tightly controlled in medicines. We will discuss the reasons behind the differences, and in a panel session will explore whether there are possibilities for greater alignment between the sectors.

Deadlines

Downloads

Impurities in Food and Pharmaceuticals - Programme

Speakers

Chris Waine Senior Toxicologist, bibra toxicology advice and consulting, United Kingdom
Dr. Martin Rose Independent Consultant, United Kingdom
Kevin Hughes Manager, Regulatory Affairs, Colorcon, United Kingdom
Dr. Rhodri Evans Head of Food Safety and Regulatory Affairs, Exponent, United Kingdom
Robert Cordina Senior Associate Principal Scientist, Mondelez, United Kingdom
Chara Tsoulli Senior Toxicological Risk Assessor, UK Food Standards Agency, United Kingdom
Dr. Lisa Hinchliffe Independent Consultant, United Kingdom
Dr. Matt Popkin Senior Director, GSK, United Kingdom
Dr. Gair Ford Regulatory CMC Director, Astrazeneca, United Kingdom

Venue

The Royal Society of Chemistry

The Royal Society of Chemistry, Burlington House, Piccadilly, London, W1J 0BA, United Kingdom

Useful links

Venue information More information about the venue

Committee

Organised by

Jointly organised by the RSC Toxicology Group, the RSC Food Group and the Joint Pharmaceutical Analysis Group

Contact information

Share:

Impurities in Food and Pharmaceuticals - can Risk Assessment and Regulation be Aligned?